Source article: https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-protects-older-adults-and-drug-protects-babies-less-so

Recent research indicates that medical protection against RSV significantly diminishes over time for both the elderly and infants. A study of US veterans aged 60 and older revealed that vaccine effectiveness against infection and hospitalization dropped substantially over an eighteen-month period, particularly among the immunocompromised. Similarly, data from Europe regarding the monoclonal antibody nirsevimab showed strong initial defense for babies, yet this preventative power waned after seven months. Because of these findings, health experts are considering the necessity of booster doses to maintain immunity across multiple viral seasons. Despite the availability of these treatments, low uptake remains a concern due to vaccine fatigue and a lack of public awareness regarding the severity of RSV. Moving forward, real-world monitoring continues to be essential for refining clinical guidance and protecting vulnerable populations.